0001104659-16-088983.txt : 20160111 0001104659-16-088983.hdr.sgml : 20160111 20160111080021 ACCESSION NUMBER: 0001104659-16-088983 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20160111 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160111 DATE AS OF CHANGE: 20160111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Envision Healthcare Holdings, Inc. CENTRAL INDEX KEY: 0001578318 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 450832318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36048 FILM NUMBER: 161335073 BUSINESS ADDRESS: STREET 1: 6200 S. SYRACUSE WAY, SUITE 200 CITY: GREENWOOD VILLAGE STATE: CO ZIP: 80111 BUSINESS PHONE: (303) 495-1200 MAIL ADDRESS: STREET 1: 6200 S. SYRACUSE WAY, SUITE 200 CITY: GREENWOOD VILLAGE STATE: CO ZIP: 80111 8-K 1 a16-1625_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 


 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported):  January 11, 2016

 

 

ENVISION HEALTHCARE HOLDINGS, INC.

(Exact name of each registrant as specified in its charter)

 

Delaware

 

001-36048

 

45-0832318

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Numbers)

 

Identification Nos.)

 

6200 S. Syracuse Way, Suite 200, Greenwood Village, Colorado

 

80111

(Address of principal executive offices)

 

(Zip Code)

 

(303) 495-1200

(Each registrant’s telephone number, including area code)

 


 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02.  Results of Operations and Financial Condition.

 

On January 11, 2016, Envision Healthcare Holdings, Inc. issued a press release announcing its financial outlook for 2016.  A copy of the press release is furnished as Exhibit 99.1 to this report.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)                                 Exhibits.

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press Release dated January 11, 2016.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ENVISION HEALTHCARE HOLDINGS, INC.

 

(Registrant)

 

 

 

 

January 11, 2016

By:

/s/ Craig A. Wilson

 

 

Craig A. Wilson

 

 

Senior Vice President, General Counsel and Secretary

 

2



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press Release dated January 11, 2016.

 

3


EX-99.1 2 a16-1625_1ex99d1.htm EX-99.1

Exhibit 99.1

 

GRAPHIC

 

Contact:

Bob Kneeley

 

303-495-1245

 

bob.kneeley@evhc.net

 

Envision Healthcare Holdings, Inc. Issues 2016 Outlook,
Expects Adjusted EBITDA of $715 to $740 Million

 

Greenwood Village, Colo. — January 11, 2016 — Envision Healthcare Holdings, Inc. (Envision) (NYSE: EVHC) issued its financial outlook for 2016.

 

Envision expects to earn Adjusted EBITDA of $715 million to $740 million, or $1.43 to $1.51 on an Adjusted earnings per share basis during 2016.

 

Envision’s outlook includes anticipated growth from organic sources, including same-store rate and volume, growth from new contract wins and margin enhancements at its EmCare segment.  Envision’s outlook also incorporates contributions from acquisitions completed during 2015, including the acquisitions of Rural/Metro Corporation and Questcare Medical Services, which were completed in the fourth quarter.  Envision’s outlook for 2016 does not incorporate contributions from incremental acquisitions that may be completed during the year.

 

Envision expects its 2016 first quarter Adjusted EBITDA to be approximately 20 to 21 percent of its annual outlook, as a result of normal expense seasonality, including higher payroll taxes in the first quarter, particularly for its EmCare segment.

 

Envision’s management is scheduled to present at the JP Morgan Healthcare conference in San Francisco on Wednesday, January 13, 2016, at 4 p.m. Pacific Time.   A live audio webcast of the presentation will be available on the investor relations section of Envision’s website at investor.evhc.net, and an archived webcast will be available at the same site through February 13, 2016.

 



 

About Envision Healthcare Holdings, Inc.

 

Envision Healthcare Holdings, Inc., offers an array of physician-led healthcare-related services to consumers, hospitals, healthcare systems, health plans and local, state and national government entities. The organization provides care across a broad patient continuum via American Medical Response, Inc. (AMR), EmCare Holdings, Inc. (EmCare) and Evolution Health, LLC (Evolution Health). AMR provides community-based medical transportation services, including emergency (‘911’), non-emergency, managed transportation, air ambulance and disaster response. EmCare’s integrated facility-based physician services include emergency, anesthesiology, hospitalist/inpatient care, radiology, tele-radiology and surgery. Evolution Health’s innovative and comprehensive care coordination solutions result in improved patient care delivery across a number of healthcare settings. Envision Healthcare is headquartered in Greenwood Village, Colorado. For additional information, visit www.evhc.net.

 

Safe Harbor Disclosures

 

Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our 2016 Adjusted EBITDA and Adjusted EPS guidance, objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.  Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in our filings with the Securities and Exchange Commission from time to time, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Factors that could cause future results to differ materially from those provided in this press release include, but are not limited to: failure to implement our business strategies, the loss of existing contracts; failure to accurately assess costs under new contracts; our ability to integrate acquisitions; competition in markets we serve; the cost of required capital expenditures; retention of our senior management; our ability to maintain or implement information systems; the impact of labor union representation; failure to comply with extensive and complex government regulation of our industry; the impact of changes in the healthcare sector; our ability to service our debt obligations; and other factors discussed in our filings with the Securities and Exchange Commission.

 

Any forward-looking statements herein are made as of the date of this press release, and we undertake no duty to update or revise any such statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties.

 

2



 

Non-GAAP Financial Measures

 

In this press release, we refer to Adjusted EBITDA and Adjusted EPS.  These are financial measures commonly used by management and investors as performance measures and liquidity indicators that are not calculated and presented in accordance with generally accepted accounting principles (GAAP) in the United States of America.  The items excluded from these non-GAAP measures are important in understanding the Company’s financial performance, and should not be considered in isolation of, or as an alternative to, GAAP financial measures.  These non-GAAP measures may not be comparable to similarly titled measures of other companies. Reconciliations for the forward-looking full-year 2016 Adjusted EBITDA and Adjusted EPS projections presented in this press release are not being provided due to the number of variables in the projected full-year 2016 Adjusted EBITDA and Adjusted EPS ranges and thus EVHC does not have sufficient data to accurately estimate the individual adjustments for such reconciliations.  Envision defines Adjusted EBITDA as net income (loss) before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), loss on early debt extinguishment, other income (expense), net, realized gains (losses) on investments, interest expense, net, equity-based compensation expense, transaction costs related to acquisition activities, related-party management fees, restructuring and other charges, severance and related costs, adjustment to net loss (income) attributable to non-controlling interest due to deferred taxes, and depreciation and amortization expense.  Adjusted EPS is defined as diluted earnings per share adjusted for expenses related to EVHC’s secondary offerings, amortization expense, equity-based compensation expense, restructuring and other charges and loss on early debt extinguishment, net of an estimated tax benefit.

 

3


GRAPHIC 3 g16251bai001.jpg GRAPHIC begin 644 g16251bai001.jpg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g16251mmi001.jpg GRAPHIC begin 644 g16251mmi001.jpg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